Inflammatory Bowel Disease
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global IBD drug development, clinical trials, regulatory approvals, and market trends for investors and pharma BD.
Showing 1–8 of 8 articles
Quick answer
NovaPharmaNews Inflammatory Bowel Disease hub for FDA covers 8 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria
J&J reports positive Phase 3 Tremfya data in ulcerative colitis
Abivax colitis drug hits goal, but cancer cases rattle investors
Abivax Ulcerative Colitis Drug Shows Strong Efficacy, But Cases of Cancer Raise Concerns
Abivax Stock Plummets Amid Safety Concerns in Ulcerative Colitis Trial
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
Obefazimod: Abivax Ulcerative Colitis Drug Faces Efficacy vs. Safety Scrutiny
FDA Approves Inflammex: Novel Biologic for Ulcerative Colitis
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.